IDH2 and glioblastoma: In addition to considering detailed molecular data, a larger study sample will therefore maximise the clinical relevance of these findings if the updated 2021 WHO CNS classifications are implemented (e.g., reassigned IDH-mutated glioblastoma to IDH-mutant astrocytoma).